Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 38, 2023 - Issue 1
Submit an article Journal homepage
3,782
Views
20
CrossRef citations to date
0
Altmetric
Review Article

Selected strategies to fight pathogenic bacteria

Aiva Plotniecea Latvian Institute of Organic Synthesis, Riga, Latvia;b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Riga Stradiņš University, Riga, LatviaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2187-5693View further author information
ORCID Icon,
Arkadij Soboleva Latvian Institute of Organic Synthesis, Riga, LatviaORCID Iconhttps://orcid.org/0000-0002-5517-1240View further author information
ORCID Icon,
Claudiu T. Supuranc Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, ItalyORCID Iconhttps://orcid.org/0000-0003-4262-0323View further author information
ORCID Icon,
Fabrizio Cartac Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, ItalyORCID Iconhttps://orcid.org/0000-0002-1141-6146View further author information
ORCID Icon,
Fredrik Björklingd Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, Center for Peptide-Based Antibiotics, University of Copenhagen, Copenhagen East, DenmarkORCID Iconhttps://orcid.org/0000-0001-7018-8334View further author information
ORCID Icon,
Henrik Franzykd Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, Center for Peptide-Based Antibiotics, University of Copenhagen, Copenhagen East, DenmarkORCID Iconhttps://orcid.org/0000-0002-2822-1927View further author information
ORCID Icon,
Jari Yli-Kauhaluomae Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, Drug Research Program, University of Helsinki, Helsinki, FinlandORCID Iconhttps://orcid.org/0000-0003-0370-7653View further author information
ORCID Icon,
Koen Augustynsf Infla-Med, Centre of Excellence, University of Antwerp, Antwerp, Belgium;g Laboratory of Medicinal Chemistry, University of Antwerp, Antwerp, BelgiumORCID Iconhttps://orcid.org/0000-0002-5203-4339View further author information
ORCID Icon,
Paul Cosh Department of Pharmaceutical Sciences, Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, BelgiumORCID Iconhttps://orcid.org/0000-0003-4361-8911View further author information
ORCID Icon,
Linda De Vooghth Department of Pharmaceutical Sciences, Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, BelgiumORCID Iconhttps://orcid.org/0000-0002-8425-8601View further author information
ORCID Icon,
Matthias Govaertsh Department of Pharmaceutical Sciences, Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, BelgiumORCID Iconhttps://orcid.org/0000-0002-1290-0968View further author information
ORCID Icon,
Juliana Aizawah Department of Pharmaceutical Sciences, Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, BelgiumORCID Iconhttps://orcid.org/0000-0003-1778-9469View further author information
ORCID Icon,
Päivi Tammelai Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Drug Research Program, University of Helsinki, Helsinki, FinlandORCID Iconhttps://orcid.org/0000-0003-4697-8066View further author information
ORCID Icon &
Raivis Žalubovskisa Latvian Institute of Organic Synthesis, Riga, Latvia;j Faculty of Materials Science and Applied Chemistry, Institute of Technology of Organic Chemistry, Riga Technical University, Riga, LatviaORCID Iconhttps://orcid.org/0000-0002-9471-1342View further author information
ORCID Icon show all
Article: 2155816 | Received 27 Oct 2022, Accepted 02 Dec 2022, Published online: 11 Jan 2023

References

  • Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770–803.
  • Patridge E, Gareiss P, Kinch MS, Hoyer D. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov Today. 2016;21(2):204–207.
  • Karageorgis G, Foley DJ, Laraia L, Brakmann S, Waldmann H. Pseudo natural products—chemical evolution of natural product structure. Angew Chem Int Ed Engl. 2021;60(29):15705–15723.
  • Jukes TH. Some historical notes on chlortetracycline. Rev Infect Dis. 1985;7(5):702–707.
  • Grossman TH. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med. 2016;6(4):a025387.
  • Ronn M, Zhu Z, Hogan PC, Zhang W-Y, Niu J, Katz CE, Dunwoody N, Gilicky O, Deng Y, Hunt DK, et al. Process R&D of eravacycline: the first fully synthetic fluorocycline in clinical development. Org Process Res Dev. 2013;17(5):838–845.
  • Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm!. Trends Mol Med. 2012;18(5):263–272.
  • Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs. class a serine carbapenemases. J Med Chem. 2015;58(9):3682–3692.
  • Kahan JS, Kahan FM, Goegelman R, Currie SA, Jackson M, Stapley EO, Miller TW, Miller AK, Hendlin D, Mochales S, et al. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo)). 1979;32(1):1–12.
  • Iso Y, Irie T, Nishino Y, Motokawa K, Nishitani Y. A novel 1β-methylcarbapenem antibiotic, S-4661 synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1β-methylcarbapenems. J Antibiot. 1996;49(2):199–209.
  • Nishino Y, Kobayashi M, Shinno T, Izumi K, Yonezawa H, Masui Y, Takahira M. Practical large-scale synthesis of doripenem: a novel 1β- methylcarbapenem antibiotic. Org Process Res Dev. 2003;7(6):846–850.
  • Sipponen A, Rautio M, Jokinen J, Laakso T, Saranpaa P, Lohi J. Resin-salve from norway spruce – a potential method to treat infected chronic skin ulcers? Drug Metab Lett. 2007;1(2):143–145.
  • Manner S, Vahermo M, Skogman ME, Krogerus S, Vuorela PM, Yli-Kauhaluoma J, Fallarero A, Moreira VM. New derivatives of dehydroabietic acid target planktonic and biofilm bacteria in Staphylococcus aureus and effectively disrupt bacterial membrane integrity. Eur J Med Chem. 2015;102:68–79.
  • Hassan G, Forsman N, Wan X, Keurulainen L, Bimbo LM, Johansson L-S, Sipari N, Yli-Kauhaluoma J, Zimmermann R, Stehl S, et al. Dehydroabietylamine-based cellulose nanofibril films: a new class of sustainable biomaterials for highly efficient, broad-spectrum antimicrobial effects. ACS Sustainable Chem Eng. 2019;7(5):5002–5009.
  • Supuran CT, Winum JY. Introduction to zinc enzymes as drug targets. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken: Wiley; 2009. p. 3–12.
  • Chen AY, Adamek RN, Dick BL, Credille CV, Morrison CN, Cohen SM. Targeting metalloenzymes for therapeutic intervention. Chem Rev. 2019;119(2):1323–1455.
  • Capasso, C, Supuran, CT, Bacterial carbonic anhydrases. In: Supuran CT, Capasso C, editors. Zinc enzyme inhibitors. Topics in medicinal chemistry. Cham: Springer. Vol. 22; 2016. p. 135–152. DOI: 10.1007/7355_2016_12
  • Capasso C, Supuran CT. Developing novel bacterial targets: carbonic anhydrases as antibacterial drug targets. In: Phoenix DA, Harris F, Dennison SR, editors. Novel antimicrobial agents and strategies. Heidelberg: Wiley-Springer; 2015. p. 31–46.
  • Supuran CT. Bacterial zinc proteases as orphan targets. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken: Wiley; 2009. p. 675–704.
  • Mastrolorenzo A, Supuran CT. Botulinum toxin, tetanus toxin and anthrax lethal factor inhibitors. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken: Wiley; 2009. p. 705–720.
  • Supuran CT. Clostridium histolyticum collagenase inhibitors in the drug design. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken; Wiley; 2009. p. 721–730.
  • Smith KS, Jakubzick C, Whittam TS, Ferry JG. Carbonic anhydrase is an ancient enzyme widespread in prokaryotes. Proc Natl Acad Sci USA. 1999;96(26):15184–15189.
  • Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem. 2015;30(2):325–332.
  • Supuran CT. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7(2):168–181.
  • Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci. 2021;135(10):1233–1249.
  • Merlin C, Masters M, McAteer S, Coulson A. Why is carbonic anhydrase essential to Escherichia coli? J Bacteriol. 2003;185(21):6415–6424.
  • Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new β-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem. 2009;52(9):3116–3120.
  • Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat. 2020;30(12):963–982.
  • Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol. 2011;2:34–36.
  • Campestre C, De Luca V, Carradori S, Grande R, Carginale V, Scaloni A, Supuran CT, Capasso C. Carbonic anhydrases: New perspectives on protein functional role and inhibition in Helicobacter pylori. Front Microbiol. 2021;12:629163–12.
  • Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev. 2020;40(6):2485–2565.
  • Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473(14):2023–2032.
  • Del Prete S, Nocentini A, Supuran CT, Capasso C. Bacterial ι-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem. 2020;35(1):1060–1068.
  • Del Prete S, Bua S, Supuran CT, Capasso C. Escherichia coli γ-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors. J Enzyme Inhib Med Chem. 2020;35(1):1545–1554.
  • Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat. 2018;28(10):745–754.
  • Rahman MM, Tikhomirova A, Modak JK, Hutton ML, Supuran CT, Roujeinikova A. Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695. Gut Pathog. 2020;12. DOI: 10.1186/s13099-020-00358-5
  • Modak JK, Tikhomirova A, Gorrell RJ, Rahman MM, Kotsanas D, Korman TM, Garcia-Bustos J, Kwok T, Ferrero RL, Supuran CT, et al. Anti-Helicobacter pylori activity of ethoxzolamide. J Enzyme Inhib Med Chem. 2019;34(1):1660–1667.
  • Modak JK, Liu YC, Supuran CT, Roujeinikova A. Structure-activity relationship for sulfonamide inhibition of Helicobacter pylori α-carbonic anhydrase. J Med Chem. 2016;59(24):11098–11109.
  • Del Prete S, De Luca V, Bua S, Nocentini A, Carginale V, Supuran CT, Capasso C. The effect of substituted benzene-sulfonamides and clinically licensed drugs on the catalytic activity of CynT2, a carbonic anhydrase crucial for Escherichia coli life cycle. IJMS. 2020;21(11):4175.
  • Aspatwar A, Kairys V, Rala S, et al. Kairys Rala Parikka Bozdag Carta Supuran Parkkila Mycobacterium tuberculosis β-carbonic anhydrases: novel targets for developing antituberculosis drugs. IJMS. 2019;20(20):5153.
  • Wani TV, Bua S, Khude PS, Chowdhary AH, Supuran CT, Toraskar MP. Evaluation of sulphonamide derivatives acting as inhibitors of human carbonic anhydrase isoforms I, II and Mycobacterium tuberculosis β-class enzyme Rv3273. J Enzyme Inhib Med Chem. 2018;33(1):962–971.
  • Aspatwar A, Hammarén M, Koskinen S, Luukinen B, Barker H, Carta F, Supuran CT, Parikka M, Parkkila S. β-CA-specific inhibitor dithiocarbamate Fc14–584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. J Enzyme Inhib Med Chem. 2017;32(1):832–840.
  • Carta F, Maresca A, Covarrubias AS, Mowbray SL, Jones TA, Supuran CT. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active β-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett. 2009;19(23):6649–6654.
  • Kaur J, Cao X, Abutaleb NS, Elkashif A, Graboski AL, Krabill AD, AbdelKhalek AH, An W, Bhardwaj A, Seleem MN, et al. Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant Enterococcus. J Med Chem. 2020;63(17):9540–9562.
  • Abutaleb NS, Elkashif A, Flaherty DP, Seleem MN. In vivo antibacterial activity of acetazolamide. Antimicrob Agents Chemother. 2021;65(4):e01715-20.
  • Abutaleb NS, Elhassanny AEM, Flaherty DP, Seleem MN. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant Enterococci. PeerJ. 2021;9:e11059.
  • Hewitt CS, Abutaleb NS, Elhassanny AEM, Nocentini A, Cao X, Amos DP, Youse MS, Holly KJ, Marapaka AK, An W, et al. Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis. 2021;7(7):1969–1984.
  • Narenji H, Gholizadeh P, Aghazadeh M, Rezaee MA, Asgharzadeh M, Kafil HS. Peptide nucleic acids (PNAs): currently potential bactericidal agents. Biomed Pharmacother. 2017;93:580–588.
  • Lee HT, Kim SK, Yoon JW. Antisense peptide nucleic acids as a potential anti-infective agent. J Microbiol. 2019;57(6):423–430.
  • Wojciechowska M, Równicki M, Mieczkowski A, Miszkiewicz J, Trylska J. Antibacterial peptide nucleic acids—facts and perspectives. Molecules. 2020;25(3):559.
  • Good L, Nielsen PE. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol. 1998;16(4):355–358.
  • Good L, Awasthi SK, Dryselius R, Larsson O, Nielsen PE. Bactericidal antisense effects of peptide – PNA conjugates. Nat Biotechnol. 2001;19(4):360–364.
  • Vaara M, Porro M. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother. 1996;40(8):1801–1805.
  • Ghosal A, Nielsen PE. Potent antibacterial antisense peptide-peptide nucleic acid conjugates against Pseudomonas aeruginosa. Nucleic Acid Ther. 2012;22(5):323–334.
  • Ghosal A, Vitali A, Stach JEM, Nielsen PE. Role of SbmA in the uptake of peptide nucleic acid (PNA)-peptide conjugates in E. coli. ACS Chem Biol. 2013;8(2):360–367.
  • Goltermann L, Yavari N, Zhang M, Ghosal A, Nielsen PE. PNA length restriction of antibacterial activity of peptide-PNA conjugates in Escherichia coli through effects of the inner membrane. Front Microbiol. 2019;10(MAY):1032.
  • Yavari N, Goltermann L, Nielsen PE. Uptake, stability, and activity of antisense anti-acpP PNA-peptide conjugates in Escherichia coli and the role of SbmA. ACS Chem Biol. 2021;16(3):471–479.
  • Corbalan N, Runti G, Adler C, Covaceuszach S, Ford RC, Lamba D, Beis K, Scocchi M, Vincent PA. Functional and structural study of the dimeric inner membrane protein SbmA. J Bacteriol. 2013;195(23):5352–5361.
  • Goltermann L, Zhang M, Ebbensgaard AE, Fiodorovaite M, Yavari N, Løbner-Olesen A, Nielsen PE. Effects of LPS composition in Escherichia coli on antibacterial activity and bacterial uptake of antisense peptide-PNA conjugates. Front Microbiol. 2022;13:877377.
  • Montagner G, Bezzerri V, Cabrini G, Fabbri E, Borgatti M, Lampronti I, Finotti A, Nielsen PE, Gambari R. An antisense peptide nucleic acid against Pseudomonas aeruginosa inhibiting bacterial-induced inflammatory responses in the cystic fibrosis IB3-1 cellular model system. Int J Biol Macromol. 2017;99:492–498.
  • Hansen AM, Bonke G, Larsen CJ, Yavari N, Nielsen PE, Franzyk H. Antibacterial peptide nucleic acid-antimicrobial peptide (PNA-AMP) conjugates: antisense targeting of fatty acid biosynthesis. Bioconjug Chem. 2016;27(4):863–867.
  • Hansen AM, Bonke G, Hogendorf WFJ, Björkling F, Nielsen J, Kongstad KT, Zabicka D, Tomczak M, Urbas M, Nielsen PE, et al. Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. Eur J Med Chem. 2019;168:134–145.
  • Iubatti M, Gabas IM, Cavaco LM, Mood EH, Lim E, Bonanno F, Yavari N, Brolin C, Nielsen PE. Antisense peptide nucleic acid-diaminobutanoic acid dendron conjugates with SbmA-independent antimicrobial activity against gram-negative bacteria. ACS Infect Dis. 2022;8(5):1098–1106.
  • da Silva KE, Ribeiro SM, Rossato L, Dos Santos CP, Preza SE, Cardoso MH, Franco OL, Migliolo L, Simionatto S. Antisense peptide nucleic acid inhibits the growth of KPC-producing Klebsiella pneumoniae strain. Res Microbiol. 2021;172(4–5):103837–5.
  • Nejad AJ, Shahrokhi N, Nielsen PE. Targeting of the essential acpP, ftsZ, and rne genes in carbapenem-resistant Acinetobacter baumannii by antisense PNA precision antibacterials. Biomedicines. 2021;9(4):429.
  • Otsuka T, Brauer AL, Kirkham C, Sully EK, Pettigrew MM, Kong Y, Geller BL, Murphy TF. Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms. J Antimicrob Chemother. 2017;72(1):137–144.
  • Sugimoto S, Maeda H, Kitamatsu M, Nishikawa I, Shida M. Selective growth inhibition of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans by antisense peptide nucleic acids. Mol Cell Probes. 2019;43:45–49.
  • Popella L, Jung J, Popova K, Urica-Mitic S, Barquist L, Vogel J. Global RNA profiles show target selectivity and physiological effects of peptide-delivered antisense antibiotics. Nucleic Acids Res. 2021;49(8):4705–4724.
  • Ghosh S, Saini S, Saraogi I. Peptide nucleic acid mediated inhibition of the bacterial signal recognition particle. Chem Commun. 2018;54(59):8257–8260.
  • Równicki M, Pieńko T, Czarnecki J, Kolanowska M, Bartosik D, Trylska J. Artificial activation of Escherichia coli mazEF and hipBA toxin–antitoxin systems by antisense peptide nucleic acids as an antibacterial strategy. Front Microbiol. 2018;9(NOV):2870.
  • Wang X, Wang Y, Ling Z, Zhang C, Fu M, Wang Y, Wang S, Zhang S, Shen Z. Peptide nucleic acid restores colistin susceptibility through modulation of MCR-1 expression in Escherichia coli. J Antimicrob Chemother. 2020;75(8):2059–2065.
  • Campion C, Charbon G, Thomsen TT, Nielsen PE, Løbner-Olesen A. Antisense inhibition of the Escherichia coli NrdAB aerobic ribonucleotide reductase is bactericidal due to induction of DNA strand breaks. J Antimicrob Chemother. 2021;76(11):2802–2814.
  • Barkowsky G, Lemster A-L, Pappesch R, Jacob A, Krüger S, Schröder A, Kreikemeyer B, Patenge N. Influence of different cell-penetrating peptides on the antimicrobial efficiency of PNAs in Streptococcus pyogenes. Mol Ther Nucleic Acids. 2019;18:444–454.
  • Narenji H, Teymournejad O, Rezaee MA, Taghizadeh S, Mehramuz B, Aghazadeh M, Asgharzadeh M, Madhi M, Gholizadeh P, Ganbarov K, et al. Antisense peptide nucleic acids againstftsZ andefaA genes inhibit growth and biofilm formation of Enterococcus faecalis. Microb Pathog. 2020; 139:103907.
  • Równicki M, Dąbrowska Z, Wojciechowska M, Wierzba AJ, Maximova K, Gryko D, Trylska J. Inhibition of Escherichia coli growth by vitamin B12-peptide nucleic acid conjugates. ACS Omega. 2019;4(1):819–824.
  • Castillo JI, Równicki M, Wojciechowska M, Trylska J. Antimicrobial synergy between mRNA targeted peptide nucleic acid and antibiotics in E. coli. Bioorg Med Chem Lett. 2018;28(18):3094–3098.
  • Martínez-Guitián M, Vázquez-Ucha JC, Álvarez-Fraga L, Conde-Pérez K, Bou G, Poza M, Beceiro A. Antisense inhibition of lpxB gene expression in Acinetobacter baumannii by peptide-PNA conjugates and synergy with colistin. J Antimicrob Chemother. 2020;75(1):51–59.
  • Yamamoto K, Yamamoto N, Ayukawa S, Yasutake Y, Ishiya K, Nakashima N. Scaffold size-dependent effect on the enhanced uptake of antibiotics and other compounds by Escherichia coli and Pseudomonas aeruginosa. Sci Rep. 2022;12(1):1–12.
  • Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Møller N, He H, Poudyal A, Li J, Nation RL, Vaara T. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother. 2010;54(8):3341–3346.
  • González-García I, Mangas-Sanjuán V, Merino-Sanjuán M, Bermejo M. In vitro-in vivo correlations: general concepts, methodologies and regulatory applications. Drug Dev Ind Pharm. 2015;41(12):1935–1947.
  • Knight A. Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare. Rev Recent Clin Trials. 2008;3(2):89–96.
  • Rai J, Kaushik K. Reduction of animal sacrifice in biomedical science & research through alternative design of animal experiments. Saudi Pharm J. 2018;26(6):896–902.
  • Garattini S, Grignaschi G. Animal testing is still the best way to find new treatments for patients. Eur J Intern Med. 2017;39:32–35.
  • Freires IA, Sardi J. d C, de Castro RD, Rosalen PL. Alternative animal and non-animal models for drug discovery and development: bonus or burden? Pharm Res. 2017;34(4):681–686.
  • Jaroch K, Jaroch A, Bojko B. Cell cultures in drug discovery and development: the need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment. J Pharm Biomed Anal. 2018;147:297–312.
  • Middleton AM, Reynolds J, Cable S, Baltazar MT, Li H, Bevan S, Carmichael PL, Dent MP, Hatherell S, Houghton J, et al. Are non-animal systemic safety assessments protective? A Toolbox and workflow. Toxicol Sci. 2022;189(1):124–147.
  • Hernández Yero LY, Pinos-Rodríguez D, Gibert JM. I. Animals devoid of pulmonary system as infection models in the study of lung bacterial pathogens. Front Microbiol. 2015;6(FEB):38.
  • Lebeaux D, Chauhan A, Rendueles O, Beloin C. From in vitro to in vivo models of bacterial biofilm-related infections. Pathogens. 2013;2(2):288–356.
  • Watkins-Chow DE, Pavan WJ. Genomic copy number and expression variation within the C57BL/6J inbred mouse strain. Genome Res. 2008;18(1):60–66.
  • Mizgerd JP, Skerrett SJ. Animal models of human pneumonia. Am J Physiol Lung Cell Mol Physiol. 2008;294(3):L387–L398.
  • Irvin CG, Bates JHT. Measuring the lung function in the mouse: the challenge of size. Respir Res. 2003;4(1):1–9.
  • Bal HS, Ghoshal NG. Morphology of the terminal bronchiolar region of common laboratory mammals. Lab Anim. 1988;22(1):76–82.
  • Tyler WS. Comparative subgross anatomy of lungs. Pleuras, interlobular septa, and distal airways. Am Rev Respir Dis. 1983;128(2 Pt 2):S32–S36.
  • Jeffery PK. Morphologic features of airway surface epithelial cells and glands. Am Rev Respir Dis. 1983;128(2 Pt 2):S14–S20.
  • Pack RJ, Al-Ugaily LH, Morris G. The cells of the tracheobronchial epithelium of the mouse: a quantitative light and electron microscope study. J Anat. 1981;132(Pt 1):71.
  • Plopper CG. Comparative morphologic features of bronchiolar epithelial cells. The Clara cell. Am Rev Respir Dis. 1983;128(2 Pt 2):S37–S41.
  • Rehli M. Of mice and men: species variations of toll-like receptor expression. Trends Immunol. 2002;23(8):375–378.
  • Schneemann M, Schoeden G. Macrophage biology and immunology: man is not a mouse. J Leukoc Biol. 2007;81(3):579–579.
  • Moser C, Hougen HP, Song Z, Rygaard J, Kharazmi A, Høiby N. Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS. 1999;107(12):1093–1100.
  • Moser C, Johansen HK, Song Z, Hougen HP, Rygaard J, Høiby N. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding. C3H/HeN mice. APMIS. 1997;105(11):838–842.
  • Starke JR, Edwards MS, Langston C, Baker CJ. A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr Res. 1987;22(6):698–702.
  • Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol. 2010;300(8):584–593.
  • Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D, Di Serio C, Bragonzi A, Cirillo DM. Adaptation of Pseudomonas aeruginosa in cystic fibrosis airways influences virulence of Staphylococcus aureus in vitro and murine models of co-infection. PLOS One. 2014;9(3):e89614.
  • Bragonzi A, Farulla I, Paroni M, Twomey KB, Pirone L, Lorè NI, Bianconi I, Dalmastri C, Ryan RP, Bevivino A. Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response. PLOS One. 2012;7(12):e52330.
  • Hoffmann N, Rasmussen TB, Jensen PØ, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK, Høiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun. 2005;73(4):2504–2514.
  • Moser C, Kjaergaard S, Pressler T, Kharazmi A, Koch C, Høiby N. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS. 2000;108(5):329–335.
  • Moser C, Van Gennip M, Bjarnsholt T, Jensen PØ, Lee B, Hougen HP, Calum H, Ciofu O, Givskov M, Molin S, et al. Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. APMIS. 2009;117(2):95–107.
  • Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;63(3):534–542.
  • Jacqueline C, Roquilly A, Desessard C, Boutoille D, Broquet A, Le Mabecque V, Amador G, Potel G, Caillon J, Asehnoune K. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response. J Antimicrob Chemother. 2013;68(1):177–183.
  • Lorenz A, Pawar V, Häussler S, Weiss S. Insights into host-pathogen interactions from state-of-the-art animal models of respiratory Pseudomonas aeruginosa infections. FEBS Lett. 2016;590(21):3941–3959.
  • Louie A, Fregeau C, Liu W, Kulawy R, Drusano GL. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrob Agents Chemother. 2009;53(8):3325–3330.
  • Maciá MD, Borrell N, Segura M, Gómez C, Pérez JL, Oliver A. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(3):975–983.
  • Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC. of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(9):3923–3928.
  • van Gennip M, Moser C, Christensen LD. Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;64(6):1241–1250.
  • Cash HA, Woods DE, McCullough B, Johanson WG, Bass JA. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis. 1979;119(3):453–459.
  • Stenvang Pedersen S, Shand GH, Langvad Hansen B, Norgaard Hansen G. Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS. 1990;98(1-6):203–211.
  • ECDC. Infographic healthcare-associated infections – a threat to patient safety in Europe. European Center for Disease Prevention and control [cited 2022 Jun 22]. Available from: https://www.ecdc.europa.eu/en/publications-data/infographic-healthcare-associated-infections-threat-patient-safety-europe.
  • Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank H-P, Ducomble T, Haller S, Harder T, Klingeberg A, Sixtensson M, et al. Burden of six healthcare-associated infections on european population health: Estimating incidence-based disability-adjusted life years through a population prevalence-based modelling study. PLOS Med. 2016;13(10):e1002150.
  • Limper AH. Overview of pneumonia. In: Goldman L, Schafer AI, editors. Goldman’s Cecil medicine: twenty fourth edition. Vol. 1. Philadelphia: Saunders Elsevier; 2012. p. 587–596.
  • Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, Kollef M, Li Bassi G, Luna CM, Martin-Loeches I, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the. Eur Respir J. 2017;50(3):1700582.
  • Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46(5):888–906.
  • Güner CK, Kutlutürkan S. Role of head-of-bed elevation in preventing ventilator-associated pneumonia bed elevation and pneumonia. Nurs Crit Care. 2022;27(5):635–645.
  • Pericolini E, Colombari B, Ferretti G, Iseppi R, Ardizzoni A, Girardis M, Sala A, Peppoloni S, Blasi E. Real-time monitoring of Pseudomonas aeruginosa biofilm formation on endotracheal tubes in vitro. BMC Microbiol. 2018;18(1):1–10.
  • Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36(11):1999–2006.
  • Melsen WG, Rovers MM, Groenwold RHH, Bergmans DCJJ, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665–671.
  • Mathew E, Domínguez-Robles J, Larrañeta E, Lamprou DA. Fused deposition modelling as a potential tool for antimicrobial dialysis catheters manufacturing: new trends vs. conventional approaches. Coatings. 2019;9(8):515.
  • Bielen K, Jongers B, Malhotra-Kumar S, Jorens PG, Goossens H, Kumar-Singh S. Animal models of hospital-acquired pneumonia: current practices and future perspectives. Ann Transl Med. 2017;5(6):132.
  • Clarke LL, Grubb BR, Gabriel SE, Smithies O, Koller BH, Boucher RC. Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. Science. 1992;257(5073):1125–1128.
  • Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, Givskov M, Høiby N. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother. 2007;51(10):3677–3687.
  • Bassi GL, Senussi T, Xiol EA. Prevention of ventilator-associated pneumonia. Curr Opin Infect Dis. 2017;30(2):214–220.
  • Yanagihara K, Tomono K, Sawai T, Hirakata Y, Kadota J, Koga H, Tashiro T, Kohno S. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 1997;155(1):337–342.
  • Kaku N, Morinaga Y, Takeda K, Kosai K, Uno N, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K. Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. J Antimicrob Chemother. 2017;72(4):1123–1128.
  • Kaneko Y, Yanagihara K, Kuroki M, Ohi H, Kakeya H, Miyazaki Y, Higashiyama Y, Hirakata Y, Tomono K, Kadota JI, et al. Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia. Chemotherapy. 2001;47(6):421–429.
  • Yamada K, Yamamoto Y, Yanagihara K, Araki N, Harada Y, Morinaga Y, Izumikawa K, Kakeya H, Hasegawa H, Kohno S, et al. In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa. J Infect Chemother. 2012;18(4):472–478.
  • Burleson GR, Burleson FG. Testing human biologicals in animal host resistance models. J Immunotoxicol. 2008;5(1):23–31.
  • Zecconi A, Scali F. Staphylococcus aureus virulence factors in evasion from innate immune defenses in human and animal diseases. Immunol Lett. 2013;150(1–2):12–22.
  • Borsa ND, Pasquale M, Restrepo MI. Animal models of Pneumococcal pneumonia. IJMS. 2019;20(17):4220.
  • Berra L, De Marchi L, Yu ZX, Laquerriere P, Baccarelli A, Kolobow T. Endotracheal tubes coated with antiseptics decrease bacterial colonization of the ventilator circuits, lungs, and endotracheal tube. Anesthesiology. 2004;100(6):1446–1456.
  • Berra L, Curto F, Li Bassi G, Laquerriere P, Baccarelli A, Kolobow T. Antibacterial-coated tracheal tubes cleaned with the Mucus Shaver : a novel method to retain long-term bactericidal activity of coated tracheal tubes. Intensive Care Med. 2006;32(6):888–893.
  • Fernández-Barat L, Li Bassi G, Ferrer M, Bosch A, Calvo M, Vila J, Gabarrús A, Martínez-Olondris P, Rigol M, Esperatti M, et al. Direct analysis of bacterial viability in endotracheal tube biofilm from a pig model of methicillin-resistant Staphylococcus aureus pneumonia following antimicrobial therapy. FEMS Immunol Med Microbiol. 2012;65(2):309–317.
  • Olson ME, Harmon BG, Kollef MH. Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest. 2002;121(3):863–870.
  • Jean SS, Chang YC, Lin WC, Lee W, Sen Hsueh PR, Hsu CW. Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia. JCM. 2020;9(1):275.
  • Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev. 2006;19(4):637–657.
  • Dutta S, Sengupta P. Men and mice: relating their ages. Life Sci. 2016;152:244–248.
  • Facchini M, Fino Riva DI, Bragonzi C. A. Long term chronic Pseudomonas aeruginosa airway infection in mice. J Vis Exp. 2014;(85):e51019.
  • Zhao M, Lepak AJ, Andes DR. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorg Med Chem. 2016;24(24):6390–6400.
  • Christophersen LJ, Trøstrup H, Malling Damlund DS, Bjarnsholt T, Thomsen K, Jensen PØ, Hougen HP, Høiby N, Moser C. Bead-size directed distribution of Pseudomonas aeruginosa results in distinct inflammatory response in a mouse model of chronic lung infection. Clin Exp Immunol. 2012;170(2):222–230.
  • Kukavica-Ibrulj I, Levesque RC. Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. Lab Anim. 2008;42(4):389–412.
  • Schwab U, Abdullah LH, Perlmutt OS, Albert D, Davis CW, Arnold RR, Yankaskas JR, Gilligan P, Neubauer H, Randell SH, et al. Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus. Infect Immun. 2014;82(11):4729–4745.
  • Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 2005;13(1):34–40.
  • Waters CM, Bassler BL. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol. 2005;21:319–346.
  • Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Curr Pharm Des. 2015;21(1):5–11.
  • Qvortrup K, Hultqvist LD, Nilsson M. Small molecule anti-biofilm agents developed on the basis of mechanistic understanding of biofilm formation. Front Chem. 2019;7:742.
  • Parsek MR, Val DL, Hanzelka BL, Cronan JE, Greenberg EP. Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci USA. 1999;96(8):4360–4365.
  • Hanzelka BL, Greenberg EP. Quorum sensing in Vibrio fischeri: evidence that S-adenosylmethionine is the amino acid substrate for autoinducer synthesis. J Bacteriol. 1996;178(17):5291–5294.
  • Favre-Bonté S, Köhler T, Van Delden C. Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. J Antimicrob Chemother. 2003;52(4):598–604.
  • Uroz S, Dessaux Y, Oger P. Quorum sensing and quorum quenching: the Yin and Yang of bacterial communication. Chembiochem. 2009;10(2):205–216.
  • Zhang R-g, Pappas KM, Brace JL, Miller PC, Oulmassov T, Molyneaux JM, Anderson JC, Bashkin JK, Winans SC, Joachimiak A. Structure of a bacterial quorum-sensing transcription factor complexed with pheromone and DNA. Nature. 2002;417(6892):971–974.
  • Christiaen SEA, Brackman G, Nelis HJ, Coenye T. Isolation and identification of quorum quenching bacteria from environmental samples. J Microbiol Methods. 2011;87(2):213–219.
  • Chen F, Gao Y, Chen X, Yu Z, Li X. Quorum quenching enzymes and their application in degrading signal molecules to block quorum sensing-dependent infection. Int J Mol Sci. 2013;14(9):17477–17500.
  • Brackman G, Risseeuw M, Celen S, Cos P, Maes L, Nelis HJ, Van Calenbergh S, Coenye T. Synthesis and evaluation of the quorum sensing inhibitory effect of substituted triazolyldihydrofuranones. Bioorg Med Chem. 2012;20(15):4737–4743.
  • Morohoshi T, Shiono T, Takidouchi K, Kato M, Kato N, Kato J, Ikeda T. Inhibition of quorum sensing in Serratia marcescens AS-1 by synthetic analogs of N-acylhomoserine lactone. Appl Environ Microbiol. 2007;73(20):6339–6344.
  • Ishida T, Ikeda T, Takiguchi N, Kuroda A, Ohtake H, Kato J. Inhibition of quorum sensing in Pseudomonas aeruginosa by N-acyl cyclopentylamides. Appl Environ Microbiol. 2007;73(10):3183–3188.
  • Girennavar B, Cepeda ML, Soni KA, Vikram A, Jesudhasan P, Jayaprakasha GK, Pillai SD, Patil BS. Grapefruit juice and its furocoumarins inhibits autoinducer signaling and biofilm formation in bacteria. Int J Food Microbiol. 2008;125(2):204–208.
  • Rasmussen TB, Bjarnsholt T, Skindersoe ME, Hentzer M, Kristoffersen P, Köte M, Nielsen J, Eberl L, Givskov M. Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. J Bacteriol. 2005;187(5):1799–1814.
  • Bjarnsholt T, Jensen PØ, Rasmussen TB, Christophersen L, Calum H, Hentzer M, Hougen H-P, Rygaard J, Moser C, Eberl L, et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology. 2005;151(Pt 12):3873–3880.
  • Jakobsen TH, van Gennip M, Phipps RK, Shanmugham MS, Christensen LD, Alhede M, Skindersoe ME, Rasmussen TB, Friedrich K, Uthe F, et al. Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob Agents Chemother. 2012;56(5):2314–2325.
  • Barzegari A, Kheyrolahzadeh K, Hosseiniyan Khatibi SM, Sharifi S, Memar MY, Zununi Vahed S. The battle of probiotics and their derivatives against biofilms. Infect Drug Resist. 2020;13:659–672.
  • Gomaa EZ. Antimicrobial and anti-adhesive properties of biosurfactant produced by lactobacilli isolates, biofilm formation and aggregation ability. J Gen Appl Microbiol. 2013;59(6):425–436.
  • Tan Y, Leonhard M, Moser D, Schneider-Stickler B. Inhibition activity of Lactobacilli supernatant against fungal-bacterial multispecies biofilms on silicone. Microb Pathog. 2017;113:197–201.
  • Sharma V, Harjai K, Shukla G. Effect of bacteriocin and exopolysaccharides isolated from probiotic on P. aeruginosa PAO1 biofilm. Folia Microbiol (Praha)). 2018;63(2):181–190.
  • Merghni A, Dallel I, Noumi E, Kadmi Y, Hentati H, Tobji S, Ben Amor A, Mastouri M. Antioxidant and antiproliferative potential of biosurfactants isolated from Lactobacillus casei and their anti-biofilm effect in oral Staphylococcus aureus strains. Microb Pathog. 2017;104:84–89.
  • Kim Y, Oh S, Kim SH. Released exopolysaccharide (r-EPS) produced from probiotic bacteria reduce biofilm formation of enterohemorrhagic Escherichia coli O157:H7. Biochem Biophys Res Commun. 2009;379(2):324–329.
  • Pan D, Mei X. Antioxidant activity of an exopolysaccharide purified from Lactococcus lactis subsp. lactis 12. Carbohydr Polym. 2010;80(3):908–914.
  • Wasfi R, Abd El-Rahman OA, Zafer MM, Ashour HM. Probiotic Lactobacillus sp. inhibit growth, biofilm formation and gene expression of caries‐inducing Streptococcus mutans. J Cell Mol Med. 2018;22(3):1972–1983.
  • Kiymaci ME, Altanlar N, Gumustas M, Ozkan SA, Akin A. Quorum sensing signals and related virulence inhibition of Pseudomonas aeruginosa by a potential probiotic strain’s organic acid. Microb Pathog. 2018;121:190–197.
  • Fong FLY, Shah NP, Kirjavainen P, El-Nezami H. Mechanism of action of probiotic bacteria on intestinal and systemic immunities and antigen-presenting cells. Int Rev Immunol. 2016;35(3):179–188.
  • Maccelli A, Carradori S, Puca V, Sisto F, Lanuti P, Crestoni ME, Lasalvia A, Muraro R, Bysell H, Di Sotto A, et al. Correlation between the antimicrobial activity and metabolic profiles of cell free supernatants and membrane vesicles produced by Lactobacillus reuteri DSM 17938. Microorganisms. 2020;8(11):1653–22.
  • Rigauts C, Aizawa J, Taylor SL, Rogers GB, Govaerts M, Cos P, Ostyn L, Sims S, Vandeplassche E, Sze M, et al. Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. Eur Respir J. 2022;59(5):2101293.
  • European Centre for Disease Prevention and Control (ECDC). Summary of the latest data on antibiotic resistance in the European Union. Euro-CDC; 2012, p. 1–4. [cited 2022 Jun 27]. Available from: https://www.ecdc.europa.eu/en/publications-data/summary-latest-data-antibiotic-resistance-european-union.
  • Marchianò V, Matos M, Serrano-Pertierra E, Gutiérrez G, Blanco-López MC. Vesicles as antibiotic carrier: state of art. Int J Pharm. 2020;585:119478.
  • European Commission. EU action on antimicrobial resistance | Public Health [cited 2022 Jun 22]. https://ec.europa.eu/health/antimicrobial-resistance/eu-action-on-antimicrobial-resistance_en.
  • Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106(Pt A):148–156.
  • Jan T, Iqbal J, Ismail M, Badshah N, Mansoor Q, Arshad A, Ahkam QM. Synthesis, physical properties and antibacterial activity of metal oxides nanostructures. Mater Sci Semicond Process. 2014;21:154–160.
  • Vega-Jiménez AL, Vázquez-Olmos AR, Acosta-Gío E, Álvarez-Pérez MA. In vitro antimicrobial activity evaluation of metal oxide nanoparticles. In: Koh KS, Wong VL, editors. Nanoemulsions – properties, fabrications and applications. London: IntechOpen; 2019. p. 1–18.
  • Ghafelehbashi R, Akbarzadeh I, Tavakkoli Yaraki M, Lajevardi A, Fatemizadeh M, Heidarpoor Saremi L. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm. 2019;569:118580.
  • Ranghar S, Sirohi P, Verma P, Agarwal V. Nanoparticle-based drug delivery systems: promising approaches against infections. Braz Arch Biol Technol. 2013;57(2):209–222.
  • Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124.
  • Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193.
  • Eleraky NE, Allam A, Hassan SB, Omar MM. Nanomedicine fight against antibacterial resistance: an overview of the recent pharmaceutical innovations. Pharmaceutics. 2020;12(2):142.
  • Miller KP, Wang L, Benicewicz BC, Decho AW. Inorganic nanoparticles engineered to attack bacteria. Chem Soc Rev. 2015;44(21):7787–7807.
  • Lah NAC, Samykano M, Trigueros S. Nanoscale metal particles as nanocarriers in targeted drug delivery system. J Nanomedicine Res. 2016;4(2):2–7.
  • McNamara K, Tofail SAM. Nanoparticles in biomedical applications. Adv Phys X. 2017;2(1):54–88.
  • Długosz O, Szostak K, Staroń A, Pulit-Prociak J, Banach M. Methods for reducing the toxicity of metal and metal oxide NPs as biomedicine. Materials. 2020;13(2):279.
  • Beyth N, Houri-Haddad Y, Domb A, Khan W, Hazan R. Alternative antimicrobial approach: nano-antimicrobial materials. Evidence-Based Complement Altern Med. 2015;2015:1–16.
  • Aderibigbe BA. Metal-based nanoparticles for the treatment of infectious diseases. Molecules. 2017;22(8):1370.
  • Zhang X-F, Liu Z-G, Shen W, Gurunathan S. Silver nanoparticles: Synthesis, characterization, properties, applications, and therapeutic approaches. IJMS. 2016;17(9):1534.
  • Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009;27(1):76–83.
  • Kim JS, Kuk E, Yu KN, Kim J-H, Park SJ, Lee HJ, Kim SH, Park YK, Park YH, Hwang C-Y, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine. 2007;3(1):95–101.
  • Avalos A, Haza AI, Mateo D, Morales P. Interactions of manufactured silver nanoparticles of different sizes with normal human dermal fibroblasts. Int Wound J. 2016;13(1):101–109.
  • Aditya NP, Vathsala PG, Vieira V, Murthy RSR, Souto EB. Advances in nanomedicines for malaria treatment. Adv Colloid Interface Sci. 2013;201–202:1–17.
  • Poulose S, Panda T, Nair PP, Théodore T. Biosynthesis of silver nanoparticles. J Nanosci Nanotechnol. 2014;14(2):2038–2049.
  • Panacek A, Kvítek L, Prucek R, Kolar M, Vecerova R, Pizúrova N, Sharma VK, Nevecna T, Zboril R. Silver colloid nanoparticles: Synthesis, characterization, and their antibacterial activity. J Phys Chem B. 2006;110(33):16248–16253.
  • De Simone S, Gallo AL, Paladini F, Sannino A, Pollini M. Development of silver nano-coatings on silk sutures as a novel approach against surgical infections. J Mater Sci Mater Med. 2014;25(9):2205–2214.
  • Leid JG, Ditto AJ, Knapp A, Shah PN, Wright BD, Blust R, Christensen L, Clemons CB, Wilber JP, Young GW, et al. In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria. J Antimicrob Chemother. 2012;67(1):138–148.
  • Chernousova S, Epple M. Silver as antibacterial agent: Ion, nanoparticle, and metal. Angew Chem Int Ed Engl. 2013;52(6):1636–1653.
  • Panáček A, Kolář M, Večeřová R, Prucek R, Soukupová J, Kryštof V, Hamal P, Zbořil R, Kvítek L. Antifungal activity of silver nanoparticles against Candida spp. Biomaterials. 2009;30(31):6333–6340.
  • Silver S. Bacterial silver resistance: Molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev. 2003;27(2-3):341–353.
  • Ug A, Ceylan O. Occurrence of resistance to antibiotics, metals, and plasmids in clinical strains of Staphylococcus spp. Arch Med Res. 2003;34(2):130–136.
  • Tolaymat TM, El Badawy AM, Genaidy A, Scheckel KG, Luxton TP, Suidan M. An evidence-based environmental perspective of manufactured silver nanoparticle in syntheses and applications: a systematic review and critical appraisal of peer-reviewed scientific papers. Sci Total Environ. 2010;408(5):999–1006.
  • Bartłomiejczyk T, Lankoff A, Kruszewski M, Szumiel I. Silver nanoparticles – allies or adversaries? Ann Agric Environ Med. 2013;20(1):48–54.
  • Majdalawieh A, Kanan MC, El-Kadri O, Kanan SM. Recent advances in gold and silver nanoparticles: synthesis and applications. J Nanosci Nanotechnol. 2014;14(7):4757–4780.
  • Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;12:7291–7309.
  • Khurana C, Vala AK, Andhariya N, Pandey OP, Chudasama B. Antibacterial activities of silver nanoparticles and antibiotic-adsorbed silver nanoparticles against biorecycling microbes. Environ Sci Process Impacts. 2014;16(9):2191–2198.
  • Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomed Nanotechnol Biol Med. 2007;3(2):168–171.
  • Kubo A-L, Capjak I, Vrček IV, Bondarenko OM, Kurvet I, Vija H, Ivask A, Kasemets K, Kahru A. Antimicrobial potency of differently coated 10 and 50 nm silver nanoparticles against clinically relevant bacteria Escherichia coli and Staphylococcus aureus. Colloids Surf B Biointerfaces. 2018;170:401–410.
  • Grande R, Sisto F, Puca V, Carradori S, Ronci M, Aceto A, Muraro R, Mincione G, Scotti L. Antimicrobial and antibiofilm activities of new synthesized silver ultra-nanoclusters (SUNCs) against Helicobacter pylori. Front Microbiol. 2020;11:1705.
  • Dakal TC, Kumar A, Majumdar RS, Yadav V. Mechanistic basis of antimicrobial actions of silver nanoparticles. Front Microbiol. 2016;7(NOV):1831.
  • Sánchez-López E, Gomes D, Esteruelas G, Bonilla L, Lopez-Machado AL, Galindo R, Cano A, Espina M, Ettcheto M, Camins A, et al. Metal-based nanoparticles as antimicrobial agents: an overview. Nanomaterials. 2020;10(2):292.
  • Ciriminna R, Albo Y, Pagliaro M. New antivirals and antibacterials based on silver nanoparticles. ChemMedChem. 2020;15(17):1619–1623.
  • Puca V, Traini T, Guarnieri S, Carradori S, Sisto F, Macchione N, Muraro R, Mincione G, Grande R. The antibiofilm effect of a medical device containing TiAb on microorganisms associated with surgical site infection. Molecules. 2019;24(12):2280.
  • Gerber A, Bundschuh M, Klingelhofer D, Groneberg DA. Gold nanoparticles: recent aspects for human toxicology. J Occup Med Toxicol. 2013;8(1):32–36.
  • Her S, Jaffray DA, Allen C. Gold nanoparticles for applications in cancer radiotherapy: mechanisms and recent advancements. Adv Drug Deliv Rev. 2017;109:84–101.
  • Shamaila S, Zafar N, Riaz S, Sharif R, Nazir J, Naseem S. Gold nanoparticles: An efficient antimicrobial agent against enteric bacterial human pathogen. Nanomaterials. 2016;6(4):71.
  • MubarakAli D, Thajuddin N, Jeganathan K, Gunasekaran M. Plant extract mediated synthesis of silver and gold nanoparticles and its antibacterial activity against clinically isolated pathogens. Colloids Surf B Biointerfaces. 2011;85(2):360–365.
  • Ayaz Ahmed KB, Subramanian S, Sivasubramanian A, Veerappan G, Veerappan A. Preparation of gold nanoparticles using Salicornia brachiata plant extract and evaluation of catalytic and antibacterial activity. Spectrochim Acta A Mol Biomol Spectrosc. 2014;130:54–58.
  • Yougbare S, Chang T-K, Tan S-H, Kuo J-C, Hsu P-H, Su C-Y, Kuo T-R. Antimicrobial gold nanoclusters: recent developments and future perspectives. IJMS. 2019;20(12):2924.
  • Abbaszadegan A, Ghahramani Y, Gholami A, Hemmateenejad B, Dorostkar S, Nabavizadeh M, Sharghi H. The effect of charge at the surface of silver nanoparticles on antimicrobial activity against gram-positive and gram-negative bacteria: A preliminary study. J Nanomater. 2015;2015:1–8.
  • Losasso C, Belluco S, Cibin V, Zavagnin P, Mičetić I, Gallocchio F, Zanella M, Bregoli L, Biancotto G, Ricci A. Antibacterial activity of silver nanoparticles: sensitivity of different Salmonella serovars. Front Microbiol. 2014;5(MAY):227.
  • Zia R, Riaz M, Farooq N, Qamar A, Anjum S. Antibacterial activity of Ag and Cu nanoparticles synthesized by chemical reduction method: a comparative analysis. Mater Res Express. 2018;5(7):075012.
  • Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomedicine. 2017;12:1227–1249.
  • Rajendran K, Anwar A, Khan NA, Siddiqui R. Brain-eating amoebae: Silver nanoparticle conjugation enhanced efficacy of anti-amoebic drugs against Naegleria fowleri. ACS Chem Neurosci. 2017;8(12):2626–2630.
  • Faedmaleki F, Shirazi FH, Salarian AA, Ashtiani HA, Rastegar H. Toxicity effect of silver nanoparticles on mice liver primary cell culture and HepG2 cell line. Iran J Pharm Res. 2014;13(1):235–242.
  • Sruthi S, Ashtami J, Mohanan PV. Biomedical application and hidden toxicity of zinc oxide nanoparticles. Mater Today Chem. 2018;10:175–186.
  • Zhang Y, Chen W, Wang S, Liu Y, Pope C. Phototoxicity of zinc oxide nanoparticle conjugates in human ovarian cancer NIH: OVCAR-3 cells. j iomed Nanotechnol. 2008;4(4):432–438.
  • Allahverdiyev AM, Abamor ES, Bagirova M, Rafailovich M. Antimicrobial effects of TiO2 and Ag2O nanoparticles against drug-resistant bacteria and leishmania parasites. Future Microbiol. 2011;6(8):933–940.
  • Wei C, Lin WY, Zainal Z, Williams NE, Zhu K, Kruzic AP, Smith RL, Rajeshwar K. Bactericidal activity of TiO2 photocatalyst in aqueous media: toward a solar-assisted water disinfection system. Environ Sci Technol. 1994;28(5):934–938.
  • Allahverdiyev AM, Abamor ES, Bagirova M, Baydar SY, Ates SC, Kaya F, Kaya C, Rafailovich M. Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro. Exp Parasitol. 2013;135(1):55–63.
  • Sudakar C, Dixit A, Regmi R, Naik R, Lawes G, Naik VM, Vaishnava PP, Toti U, Panyam J. Fe3O4 incorporated AOT-alginate nanoparticles for drug delivery. IEEE Trans Magn. 2008;44(11):2800–2803.
  • Jarosz M, Kapusta-Kołodziej J, Pawlik A, Syrek K, Sulka GD. Drug delivery systems based on titania nanostructures. In: Andronescu E, Grumezescu AM, editors. Nanostructures for drug delivery. Amsterdam: Elsevier; 2017. p. 299–326.
  • Zhang H, Wang C, Chen B, Wang X. Daunorubicin-TiO2 nanocomposites as a “smart” pH-responsive drug delivery system. Int J Nanomedicine. 2012;7:235–242.
  • Gomathi Devi L, Nagaraj B. Disinfection of Escherichia Coli gram negative bacteria using surface modified TiO2: optimization of Ag metallization and depiction of charge transfer mechanism. Photochem Photobiol. 2014;90(5):1089–1098.
  • Ungureanu C, Popescu S, Purcel G, Tofan V, Popescu M, Sălăgeanu A, Pîrvu C. Improved antibacterial behavior of titanium surface with torularhodin-polypyrrole film. Mater Sci Eng C Mater Biol Appl. 2014;42:726–733.
  • Petronella F, Truppi A, Striccoli M, Curri ML, Comparelli R. Photocatalytic application of Ag/TiO2 hybrid nanoparticles. In: Mohapatra S, Nguyen TA, Nguyen-Tri P, editors. Noble metal-metal oxide hybrid nanoparticles: fundamentals and applications. Sawston: Woodhead Publishing; 2018. p. 373–394.
  • Mohammad MR, Ahmed DS, Mohammed MKA. Synthesis of Ag-doped TiO2 nanoparticles coated with carbon nanotubes by the sol–gel method and their antibacterial activities. J Sol-Gel Sci Technol. 2019;90(3):498–509.
  • Harandi FN, Khorasani AC, Shojaosadati SA, Hashemi-Najafabadi S. Surface modification of electrospun wound dressing material by Fe2O3 nanoparticles incorporating Lactobacillus strains for enhanced antimicrobial and antibiofilm activity. Surf. Interfaces. 2022; 28:101592.
  • Sihem L, Hanine D, Faiza B. Antibacterial activity of α-Fe2O3 and α-Fe2O3@Ag nanoparticles prepared by Urtica leaf extract. Nanotechnol Russia. 2020;15(2):198–203.
  • Li D, Shen M, Xia J, Shi X. Recent developments of cancer nanomedicines based on ultrasmall iron oxide nanoparticles and nanoclusters. Nanomedicine. 2021;16(8):609–612.
  • Anghel AG, Grumezescu AM, Chirea M, Grumezescu V, Socol G, Iordache F, Oprea AE, Anghel I, Holban AM. MAPLE fabricated Fe3O4@Cinnamomum verum antimicrobial surfaces for improved gastrostomy tubes. Molecules. 2014;19(7):8981–8994.
  • Alavijeh MS, Bani MS, Rad I, Hatamie S, Zomorod MS, Haghpanahi M. Antibacterial properties of ferrimagnetic and superparamagnetic nanoparticles: a comparative study. J Mech Sci Technol. 2021;35(2):815–821.
  • Taylor EN, Webster TJ. The use of superparamagnetic nanoparticles for prosthetic biofilm prevention. Int J Nanomedicine. 2009;4:145–152.
  • Taylor EN, Kummer KM, Durmus NG, Leuba K, Tarquinio KM, Webster TJ. Superparamagnetic iron oxide nanoparticles (SPION) for the treatment of antibiotic-resistant biofilms. Small. 2012;8(19):3016–3027.
  • Armijo LM, Wawrzyniec SJ, Kopciuch M, Brandt YI, Rivera AC, Withers NJ, Cook NC, Huber DL, Monson TC, Smyth HDC, et al. Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms. J Nanobiotechnol. 2020;18(1):1–27.
  • Subbiahdoss G, Sharifi S, Grijpma DW, Laurent S, van der Mei HC, Mahmoudi M, Busscher HJ. Magnetic targeting of surface-modified superparamagnetic iron oxide nanoparticles yields antibacterial efficacy against biofilms of gentamicin-resistant Staphylococci. Acta Biomater. 2012;8(6):2047–2055.
  • Mahmoudi M, Serpooshan V. Silver-coated engineered magnetic nanoparticles are promising for the success in the fight against antibacterial resistance threat. ACS Nano. 2012;6(3):2656–2664.
  • Niemirowicz-Laskowska K, Głuszek K, Piktel E, Pajuste K, Durnaś B, Król G, Wilczewska AZ, Janmey PA, Plotniece A, Bucki R. Bactericidal and immunomodulatory properties of magnetic nanoparticles functionalized by 1,4-dihydropyridines. Int J Nanomedicine. 2018;13:3411–3424.
  • Gudkov SV, Burmistrov DE, Serov DA, Rebezov MB, Semenova AA, Lisitsyn AB. Do iron oxide nanoparticles have significant antibacterial properties? Antibiotics. 2021;10(7):884.
  • Innocenzi P, Stagi L. Carbon-based antiviral nanomaterials: graphene, C-dots, and fullerenes. A perspective. Chem Sci. 2020;11(26):6606–6622.
  • Dizaj SM, Mennati A, Jafari S, Khezri K, Adibkia K. Antimicrobial activity of carbon-based nanoparticles. Adv Pharm Bull. 2015;5(1):19–23.
  • Smith SC, Rodrigues DF. Carbon-based nanomaterials for removal of chemical and biological contaminants from water: a review of mechanisms and applications. Carbon N Y. 2015;91:122–143.
  • Abo-Neima SE, Motaweh HA, Elsehly EM. Antimicrobial activity of functionalised carbon nanotubes against pathogenic microorganisms. IET Nanobiotechnol. 2020;14(6):457–464.
  • Ghirardello M, Ramos-Soriano J, Galan MC. Carbon dots as an emergent class of antimicrobial agents. Nanomaterials. 2021;11(8):1877.
  • Davoodi E, Zhianmanesh M, Montazerian H, Milani AS, Hoorfar M. Nano-porous anodic alumina: fundamentals and applications in tissue engineering. J Mater Sci Mater Med. 2020;31(7):60.
  • Seaberg J, Montazerian H, Hossen MN, Bhattacharya R, Khademhosseini A, Mukherjee P. Hybrid nanosystems for biomedical applications. ACS Nano. 2021;15(2):2099–2142.
  • Chen F, Hableel G, Zhao ER, Jokerst JV. Multifunctional nanomedicine with silica: Role of silica in nanoparticles for theranostic, imaging, and drug monitoring. J Colloid Interface Sci. 2018;521:261–279.
  • Bernardos A, Piacenza E, Sancenón F, Hamidi M, Maleki A, Turner RJ, Martínez‐Máñez R. Mesoporous silica-based materials with bactericidal properties. Small. 2019;15(24):1900669.
  • Colilla M, Vallet-Regí M. Targeted stimuli-responsive mesoporous silica nanoparticles for bacterial infection treatment. IJMS. 2020;21(22):8605–8632.
  • Castillo RR, Vallet-Regí M. Recent advances toward the use of mesoporous silica nanoparticles for the treatment of bacterial infections. Int J Nanomedicine. 2021;16:4409–4430.
  • Smirnov NA, Kudryashov SI, Nastulyavichus AA, Rudenko AA, Saraeva IN, Tolordava ER, Gonchukov SA, Romanova YM, Ionin AA, Zayarny DA. Antibacterial properties of silicon nanoparticles. Laser Phys Lett. 2018;15(10):105602.
  • Selvarajan V, Obuobi S, Ee PLR. Silica nanoparticles—a versatile tool for the treatment of bacterial infections. Front Chem. 2020;8:602.
  • Valizadeh A, Mikaeili H, Samiei M, Farkhani SM, Zarghami N, Kouhi M, Akbarzadeh A, Davaran S. Quantum dots: synthesis, bioapplications, and toxicity. Nanoscale Res Lett. 2012;7(1):480–414.
  • Owusu EGA, Macrobert AJ, Naasani I, Parkin IP, Allan E, Yaghini E. Photoactivable polymers embedded with cadmium-free quantum dots and crystal violet: efficient bactericidal activity against clinical strains of antibiotic-resistant bacteria. ACS Appl Mater Interfaces. 2019;11(13):12367–12378.
  • Rajendiran K, Zhao Z, Pei DS, Fu A. Antimicrobial activity and mechanism of functionalized quantum dots. Polymers. 2019;11(10):1670.
  • Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan MH, Adibkia K. Antimicrobial activity of the metals and metal oxide nanoparticles. Mater Sci Eng C Mater Biol Appl. 2014;44:278–284.
  • Levy M, Bertram JR, Eller KA, Chatterjee A, Nagpal P. Near-infrared-light-triggered antimicrobial indium phosphide quantum dots. Angew Chem Int Ed Engl. 2019;58(33):11414–11418.
  • McCollum CR, Levy M, Bertram JR, Nagpal P, Chatterjee A. Photoexcited quantum dots as efficacious and nontoxic antibiotics in an animal model. ACS Biomater Sci Eng. 2021;7(5):1863–1875.
  • Martin-Serrano Á, Gómez R, Ortega P, Mata FJDL. Nanosystems as vehicles for the delivery of antimicrobial peptides (AMPs). Pharmaceutics. 2019;11(9):448.
  • Ferreira M, Ogren M, Dias JNR, Silva M, Gil S, Tavares L, Aires-da-Silva F, Gaspar MM, Aguiar SI. Liposomes as antibiotic delivery systems: a promising nanotechnological strategy against antimicrobial resistance. Molecules. 2021;26(7):2047.
  • Deshmukh RR, Gawale V, Kailas Bhagwat M, Ahire A, Diliprao Derle N. A review on: liposomes. World J Pharm Pharm Sci. 2016;5(3):506–517.
  • Priyanka R, Bhattacharyya S. A review on promising antibiotic therapy by novel delivery systems. Asian J Pharm Clin Res. 2018;11(5):18–24.
  • Sharma A, Kumar Arya D, Dua M, Chhatwal GS, Johri AK. Nano-technology for targeted drug delivery to combat antibiotic resistance. Expert Opin Drug Deliv. 2012;9(11):1325–1332.
  • Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001;90(6):667–680.
  • Rai A, Comune M, Ferreira L. Nanoparticle-based drug delivery systems: Promising approaches against bacterial infections. In: Ahmad I, Ahmad S, Rumbaugh K, editors. Antibacterial drug discovery to combat MDR. Singapore: Springer; 2019. p. 605–633.
  • Fang CL, Aljuffali IA, Li YC, Fang JY. Delivery and targeting of nanoparticles into hair follicles. Ther Deliv. 2014;5(9):991–1006.
  • Yeh YC, Huang TH, Yang SC, Chen CC, Fang JY. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front Chem. 2020;8:286.
  • Karami N, Moghimipour E, Salimi A. Liposomes as a novel drug delivery system: fundamental and pharmaceutical application. Asian J Pharm. 2018;12(1):S31–S41.
  • Mamizuka EM, Carmona-Ribeiro AM. Cationic liposomes as antimicrobial agents. In: Mendez-Vilas A, editors. Communicating current research and educational topics and trends in applied microbiology. Badajoz: Formatex; 2007. p. 636–647.
  • Skwarczynski M, Bashiri S, Yuan Y, Ziora ZM, Nabil O, Masuda K, Khongkow M, Rimsueb N, Cabral H, Ruktanonchai U, et al. Antimicrobial activity enhancers: towards smart delivery of antimicrobial agents. Antibiotics. 2022; 11(3):412.
  • Kang SN, Hong SS, Kim SY, Oh H, Lee MK, Lim SJ. Enhancement of liposomal stability and cellular drug uptake by incorporating tributyrin into celecoxib-loaded liposomes. Asian J Pharm Sci. 2013;8(2):138–148.
  • Gonzalez Gomez A, Xu C, Hosseinidoust Z. Preserving the efficacy of glycopeptide antibiotics during nanoencapsulation in liposomes. ACS Infect Dis. 2019;5(10):1794–1801.
  • Yang Z, Liu J, Gao J, Chen S, Huang G. Chitosan coated vancomycin hydrochloride liposomes: characterizations and evaluation. Int J Pharm. 2015;495(1):508–515.
  • Gonzalez Gomez A, Hosseinidoust Z. Liposomes for antibiotic encapsulation and delivery. ACS Infect Dis. 2020;6(5):896–908.
  • Moorcroft SCT, Jayne DG, Evans SD, Ong ZY. Stimuli-responsive release of antimicrobials using hybrid inorganic nanoparticle-associated drug-delivery systems. Macromol Biosci. 2018;18(12):1800207.
  • Devnarain N, Osman N, Fasiku VO, et al. Intrinsic stimuli-responsive nanocarriers for smart drug delivery of antibacterial agents—an in-depth review of the last two decades. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology. 2021;13(1):e1664.
  • Zhang W, Hu E, Wang Y, Miao S, Liu Y, Hu Y, Liu J, Xu B, Chen D, Shen Y. Emerging antibacterial strategies with application of targeting drug delivery system and combined treatment. Int J Nanomedicine. 2021;16:6141–6156.
  • Wang DY, van der Mei HC, Ren Y, Busscher HJ, Shi L. Lipid-based antimicrobial delivery-systems for the treatment of bacterial infections. Front Chem. 2020;7:872.
  • Cheung Lam AH, Sandoval N, Wadhwa R, Gilkes J, Do TQ, Ernst W, Chiang S-M, Kosina S, Howard Xu H, Fujii G, et al. Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic. BMC Res Notes. 2016;9(1):1–11.
  • Rucins M, Dimitrijevs P, Pajuste K, Petrichenko O, Jackevica L, Gulbe A, Kibilda S, Smits K, Plotniece M, Tirzite D, et al. Contribution of molecular structure to self-assembling and biological properties of bifunctional lipid-like 4-(N-alkylpyridinium)-1,4-dihydropyridines. Pharmaceutics. 2019;11(3):115.
  • Richards S-J, Keenan T, Vendeville J-B, Wheatley DE, Chidwick H, Budhadev D, Council CE, Webster CS, Ledru H, Baker AN, et al. Introducing affinity and selectivity into galectin-targeting nanoparticles with fluorinated glycan ligands. Chem Sci. 2020;12(3):905–910.
  • Liu D, Chen L, Jiang S, Zhu S, Qian Y, Wang F, Li R, Xu Q. Formulation and characterization of hydrophilic drug diclofenac sodium-loaded solid lipid nanoparticles based on phospholipid complexes technology. J Liposome Res. 2014;24(1):17–26.
  • Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine. 2010;6(6):753–759.
  • Yadav N, Khatak SS, Sara UV. Solid lipid nanoparticles – a review. Int J Appl Pharm. 2013;5(2):8–18.
  • Kalhapure RS, Mocktar C, Sikwal DR, Sonawane SJ, Kathiravan MK, Skelton A, Govender T. Ion pairing with linoleic acid simultaneously enhances encapsulation efficiency and antibacterial activity of vancomycin in solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2014;117:303–311.
  • Álvarez-Paino M, Muñoz-Bonilla A, Fernández-García M. Antimicrobial polymers in the nano-world. Nanomaterials. 2017;7(2):48.
  • Xiong MH, Bao Y, Yang XZ, Zhu YH, Wang J. Delivery of antibiotics with polymeric particles. Adv Drug Deliv Rev. 2014;78:63–76.
  • Imbuluzqueta E, Lemaire S, Gamazo C, Elizondo E, Ventosa N, Veciana J, Van Bambeke F, Blanco-Prieto MJ. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin. J Antimicrob Chemother. 2012;67(9):2158–2164.
  • Karthikeyan R, Koushik OS, Kumar PV. Dendrimeric architecture for effective antimicrobial therapy. In: Sharma AK, Keservani RK, editors. Dendrimers for drug delivery. Palm Bay, FL, USA: Apple Academic Press Inc.; 2019. p. 375–405.
  • Authimoolam SP, Dziubla TD. Biopolymeric mucin and synthetic polymer analogs: their structure, function and role in biomedical applications. Polymers. 2016;8(3):71.
  • Chis AA, Dobrea C, Morgovan C, Arseniu AM, Rus LL, Butuca A, Juncan AM, Totan M, Vonica-Tincu AL, Cormos G, et al. Applications and limitations of dendrimers in biomedicine. Molecules. 2020;25(17):3982.
  • Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm. 2005;295(1–2):221–233.
  • Scorciapino MA, Serra I, Manzo G, Rinaldi AC. Antimicrobial dendrimeric peptides: structure, activity and new therapeutic applications. IJMS. 2017;18(3):542.
  • Selin M, Nummelin S, Deleu J, Ropponen J, Viitala T, Lahtinen M, Koivisto J, Hirvonen J, Peltonen L, Kostiainen MA, et al. High-generation amphiphilic janus-dendrimers as stabilizing agents for drug suspensions. Biomacromolecules. 2018;19(10):3983–3993.
  • Falanga A, Del Genio V, Kaufman EA, Zannella C, Franci G, Weck M, Galdiero S. Engineering of janus-like dendrimers with peptides derived from glycoproteins of Herpes simplex virus type 1: toward a versatile and novel antiviral platform.IJMS. 2021;22(12):6488.
  • Rabea EI, Badawy MET, Stevens CV, Smagghe G, Steurbaut W. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules. 2003;4(6):1457–1465.
  • Machul A, Mikołajczyk D, Regiel-Futyra A, Heczko PB, Strus M, Arruebo M, Stochel G, Kyzioł A. Study on inhibitory activity of chitosan-based materials against biofilm producing Pseudomonas aeruginosa strains. J Biomater Appl. 2015;30(3):269–278.
  • Han C, Romero N, Fischer S, Dookran J, Berger A, Doiron AL. Recent developments in the use of nanoparticles for treatment of biofilms. Nanotechnol Rev. 2017;6(5):383–404.
  • Li J, Zhuang S. Antibacterial activity of chitosan and its derivatives and their interaction mechanism with bacteria: current state and perspectives. Eur Polym J. 2020;138:109984.
  • Enríquez de Salamanca A, Diebold Y, Calonge M, García-Vazquez C, Callejo S, Vila A, Alonso MJ. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci. 2006;47(4):1416–1425.
  • Hassani Najafabadi A, Abdouss M, Faghihi S. Synthesis and evaluation of PEG-O-chitosan nanoparticles for delivery of poor water soluble drugs: ibuprofen. Mater Sci Eng C Mater Biol Appl. 2014;41:91–99.
  • Tan Y, Ma S, Liu C, Yu W, Han F. Enhancing the stability and antibiofilm activity of DspB by immobilization on carboxymethyl chitosan nanoparticles. Microbiol Res. 2015;178:35–41.
  • Jana S, Kumar Sen K, Gandhi A. Alginate based nanocarriers for drug delivery applications. Curr Pharm Des. 2016;22(22):3399–3410.
  • Hariyadi DM, Islam N. Current status of alginate in drug delivery. Adv Pharmacol Pharm Sci. 2020;2020(2):8886095–8886222.
  • Aldawsari MF, Ahmed MM, Fatima F, Anwer MK, Katakam P, Khan A. Development and characterization of calcium-alginate beads of apigenin: in vitro antitumor, antibacterial, and antioxidant activities. Mar Drugs. 2021;19(8):467.
  • Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011;6:877–895.
  • Hiraki J. Basic and applied studies on  ε-polylysine. J Antibact Antifung Agents. 1995;23:349–354.
  • Beyth N, Yudovin-Farber I, Perez-Davidi M, Domb AJ, Weiss EI. Polyethyleneimine nanoparticles incorporated into resin composite cause cell death and trigger biofilm stress in vivo. Proc Natl Acad Sci USA. 2010;107(51):22038–22043.
  • Taheri S, Baier G, Majewski P, Barton M, Förch R, Landfester K, Vasilev K. Synthesis and surface immobilization of antibacterial hybrid silver-poly(l-lactide) nanoparticles. Nanotechnology. 2014;25(30):305102.
  • Kho K, Cheow WS, Lie RH, Hadinoto K. Aqueous re-dispersibility of spray-dried antibiotic-loaded polycaprolactone nanoparticle aggregates for inhaled anti-biofilm therapy. Powder Technol. 2010;203(3):432–439.
  • Ghosh S, Acharyya M, Mandal SM. Novolac-based polymer-silver nanoparticles hybrid: Synthesis, characterization and antibacterial evaluation. CAPS. 2019;3(1):75–82.
  • Jiang L, Lee HW, Loo SCJ. Therapeutic lipid-coated hybrid nanoparticles against bacterial infections. RSC Adv. 2020;10(14):8497–8517.
  • Yang S, Han X, Yang Y, Qiao H, Yu Z, Liu Y, Wang J, Tang T. Bacteria-targeting nanoparticles with microenvironment-responsive antibiotic release to eliminate intracellular Staphylococcus aureus and associated infection. ACS Appl Mater Interfaces. 2018;10(17):14299–14311.
  • Dai X, Guo Q, Zhao Y, Zhang P, Zhang T, Zhang X, Li C. Functional silver nanoparticle as a benign antimicrobial agent that eradicates antibiotic-resistant bacteria and promotes wound healing. ACS Appl Mater Interfaces. 2016;8(39):25798–25807.
  • Baek J-S, Tan CH, Ng NKJ, Yeo YP, Rice SA, Loo SCJ. A programmable lipid-polymer hybrid nanoparticle system for localized, sustained antibiotic delivery to Gram-positive and Gram-negative bacterial biofilms. Nanoscale Horiz. 2018;3(3):305–311.
  • Castro NR, Pinto CSC, Santos EP, Mansur CRE. Hybrid vesicular nanosystems based on lipids and polymers applied in therapy, theranostics, and cosmetics. Crit Rev Ther Drug Carrier Syst. 2020;37(3):271–303.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.